RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0610
+0.0111 (+22.24%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.0499
Open0.0376
Bid0.0000 x 1100
Ask0.0000 x 3000
Day's Range0.0300 - 0.0610
52 Week Range0.0300 - 70.8000
Volume1031060
Avg. Volume1,437
Market Cap2.6M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
  • ACCESSWIRE

    ReShape Lifesciences Announces Third Quarter 2019 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / November 14, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, ...

  • ACCESSWIRE

    ReShape Lifesciences Announces 1-for-120 Reverse Stock Split

    SAN CLEMENTE, CA / ACCESSWIRE / November 11, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-120 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on November 12, 2019. At that time, each 120 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.

  • ACCESSWIRE

    ReShape Lifesciences to Host Third Quarter 2019 Conference Call on November 14, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, ...

  • ACCESSWIRE

    ReShape Lifesciences Announces Strategic Marketing Partnership for LAP-BAND(R)

    SAN CLEMENTE, CA / ACCESSWIRE / November 5, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, ...

  • ACCESSWIRE

    ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer

    SAN CLEMENTE, CA / ACCESSWIRE / October 30, 2019 / ReShape Lifesciences Inc. (RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Thomas Stankovich as Chief Financial Officer (CFO) effective immediately. "We are happy to have Tom join our senior leadership team as CFO," commented Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. Mr. Stankovich has over 25 years of executive leadership experience as the CFO for multiple public and private healthcare companies.

  • ACCESSWIRE

    ReShape Lifesciences Announces Attendance and Presentation at Obesity Week 2019

    SAN CLEMENTE, CA / ACCESSWIRE / October 17, 2019 / ReShape Lifesciences Inc. (RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company will be attending ObesityWeek 2019, taking place at the Mandalay Bay Resort in Las Vegas, Nevada, from November 3-7, 2019. LAP-BAND® by ReShape Lifesciences,™ which has nearly one million placements around the world, will be highlighted at the company's booth in the exhibit hall of the conference, where senior company representatives will be meeting with key clinical opinion leaders to discuss ReShape Lifesciences' commitment to its existing and emerging bariatric surgery technologies. Additionally, there will be two articles featuring the LAP-BAND in the ObesityWeek 2019 issue of Bariatric News.

  • ACCESSWIRE

    ReShape Lifesciences Enters into Early Warrant Exercise Transaction and Receives an Additional $7.65 Million in Proceeds

    SAN CLEMENTE, CA / ACCESSWIRE / September 23, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today entered into an early warrant exercise transaction with the holders of 400,000,000 Series B Warrants issued in ReShape's June 2019 private placement pursuant to a warrant exercise agreement. The early exercise of the warrants resulted in approximately $7.65 million of aggregate gross proceeds to ReShape. ReShape intends to use the net proceeds from the warrant exercise for general working capital purposes.

  • ACCESSWIRE

    ReShape Lifesciences(TM) to Participate in the H. C. Wainwright Global Investment Conference

    SAN CLEMENTE, CA / ACCESSWIRE / September 3, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the ...

  • ACCESSWIRE

    ReShape Lifesciences(TM) to Highlight Products at IFSO 24th World Congress

    SAN CLEMENTE, CA / ACCESSWIRE / August 22, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE

    ReShape Lifesciences to Host Second Quarter 2019 Conference Call on August 14, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / August 8, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE

    ReShape Lifesciences Announces CFO Resignation

    SAN CLEMENTE, CA / ACCESSWIRE / August 6, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today Scott Youngstrom will resign as Chief Financial Officer effective October 1, 2019, per his retention agreement. "We greatly appreciate the contributions Scott has made during his tenure at ReShape Lifesciences," stated Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. Scott Youngstrom, Chief Financial Officer of ReShape Lifesciences stated, "It is with mixed emotions that I announce my departure from ReShape.

  • ACCESSWIRE

    ReShape Lifesciences to Highlight LAP-Band Weight Loss Technology at ASMBS Spring Meeting

    SAN CLEMENTE, CA / ACCESSWIRE / June 18, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE

    ReShape Lifesciences Announces $8 Million Private Placement

    SAN CLEMENTE, CA / ACCESSWIRE / June 14, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with certain healthcare focused institutional investors for the sale of 400,000,000 shares of common stock (or common stock equivalents), series A warrants to purchase up to 400,000,000 shares of common stock and series B warrants to purchase up to 400,000,000 shares of common stock in a private placement at a price of $0.02 per share and associated warrants for gross proceeds of approximately $8 million. The number of shares of common stock (and common stock equivalents) issuable to the investors is subject to adjustment following the effectuation of a reverse stock split by the Company, as set forth in the definitive agreements.

  • ACCESSWIRE

    ReShape Lifesciences Strengthens Executive Leadership Team with Appointment of Kevin Condrin as Senior Vice President of Commercial

    SAN CLEMENTE, CA / ACCESSWIRE / June 4, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment ...

  • ACCESSWIRE

    ReShape Lifesciences Announces First Quarter 2019 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ACCESSWIRE

    ReShape Lifesciences to Host First Quarter 2019 Conference Call on May 20, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it ...

  • ACCESSWIRE

    ReShape Lifesciences Announces Distribution in Australia

    SAN CLEMENTE, CA / ACCESSWIRE / April 18, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that as of April 1, 2019, the company is selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market. The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND® while it was owned by Allergan and Apollo Endosurgery respectively.

  • ACCESSWIRE

    ReShape Lifesciences Announces Fourth Quarter and Full Year 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months and year ended December 31, 2018. Reported gross margins from continuing operations of 73% for the full year 2018.

  • ACCESSWIRE

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences, Inc. (OTCQB: RSLS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 1, 2019 at 4:30 ...

  • ACCESSWIRE

    ReShape Lifesciences Implants First Patient in ENDURE II Trial to Support CE Marking of ReShape Vest

    SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company has successfully implanted its first patient in the ENDURE II trial designed to support CE Marking of the ReShape VestTM. The ReShape Vest is a minimally invasive non-anatomy changing obesity solution that restricts stomach volume without cutting, stapling, or removing the stomach. In a pilot study of 17 patients who were implanted with the ReShape Vest, early clinical results showed 85% excess weight loss at one year.

  • ACCESSWIRE

    ReShape Lifesciences Announces $2 Million Convertible Note Financing

    SAN CLEMENTE, CA / ACCESSWIRE / March 29, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into a definitive agreement with certain institutional investors for a $2 million convertible note financing, which notes will be issued in a private placement. The notes will mature three months after their issuance and, if not repaid, will then initially be convertible into shares of common stock at a conversion price equal to the lesser of $0.33 and 80% of the average of the lowest two volume weighted average prices of the company's common stock during the 20 trading days prior to conversion. In connection with the financing, the company will amend the exercise price of warrants to purchase up to 8 million shares of common stock held by the investors that were issued on November 28, 2018 from $1.50 per share to $0.01 per share.

  • ACCESSWIRE

    ReShape Lifesciences Announces Appointment of Barton P. Bandy as President and Chief Executive Officer

    SAN CLEMENTE, CA / ACCESSWIRE / March 26, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Barton P. Bandy as President and Chief Executive Officer effective April 1, 2019. As previously announced, Dan W. Gladney will step down as President and Chief Executive Officer on March 31, 2019 and will continue to serve as Chairman of the Board for ReShape Lifesciences.

  • ACCESSWIRE

    ReShape Lifesciences to Host Fourth Quarter and Full Year 2018 Conference Call on April 1, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / March 19, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE

    ReShape Vest to be Showcased at 4th Annual Surgical Disruptive Technology Summit

    SAN CLEMENTE, CA / ACCESSWIRE / February 25, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company's ReShape VestTM will be discussed during a session at the 4th Annual Surgical Disruptive Technology Summit taking place at the JW Marriott Hotel in Houston, Texas from March 2-4, 2019. The Surgical Disruptive Technology Summit, which is hosted by the Department of Surgery at the University of Texas Health Science Center at Houston and the McGovern Medical School, is the pre-eminent educational forum for General, Bariatric, Colorectal, and Oncological Surgeons.

  • ACCESSWIRE

    ReShape Lifesciences to Debut LAP-BAND Technology at Minimally Invasive Surgery Symposium

    SAN CLEMENTE, CA / ACCESSWIRE / February 19, 2019 / ReShape Lifesciences Inc. (OTC PINK: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...